Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes.
Conclusions: For an initial therapy in overweight/obese patients with newly diagnosed T2D, exenatide causes a better glycemic control than metformin. This trial is registered with NCT03297879.
PMID: 29358950 [PubMed]
Source: International Journal of Endocrinology - Category: Endocrinology Tags: Int J Endocrinol Source Type: research
More News: Byetta | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fortamet | Metformin | Obesity | Study